Best 3 new drugs for 2019 - Cenobamate (SK Biopharm), Rolontis (Hanmi Pharmaceutical), VM202 (ViroMed)
Best 3 new drugs for 2019 - Cenobamate (SK Biopharm), Rolontis (Hanmi Pharmaceutical), VM202 (ViroMed)
  • Kim Min-jee
  • 승인 2019.01.02 10:46
  • 댓글 0
이 기사를 공유합니다

The year 2019 is a time when South Korean companies' performance in developing new medicines is in full swing. Which new drug has the potential to take Korean pharmaceutical and bio industries to jump to another higher level? It was recommended by analysts in charge of pharmaceuticals and bios at securities companies and selected "Best 3 new drugs to be noteworthy in 2019."

▶1. Cenobamate (SK Biopharm)

Cenobamate, which was developed by SK Biopharm, is a new drug for cerebral palsy. Although many treatments have been released so far, about half of the patients still suffer from seizures, so there are many demands for new ones. As a result of clinical second and third phases, Cenobamate is expected to show a high rate of reduction in the frequency of seizures compared to its competitors.

▶2. Rolontis (Hanmi Pharmaceutical)

Hanmi Pharmaceutical boasting of a strong new drug pipeline is one of the most anticipating pharmaceutical companies in 2019. What attracts attention is the drug "Rolontis," which is a treatment for neutropenia that has been exported to the U.S. Spectrum.

After completing two three-phase clinical tests of validity and safety after technology exports in 2012, Rolontis is expected to apply for the BLA (Biologics License Application within this year. It is expected to get the FDA approval in 2019 at the earliest.

▶3. VM202 (ViroMed)

ViroMed is preparing to enter the U.S. market with its own new drug. "VM202" of ViroMed is a gene therapy that injects into muscle and functions to produce HGF (hepatocyte growth factor) proteins.

Currently, it is conducting three clinical tests for patients with DPN and PAD in the U.S. The DPN is waiting for results after drug administration for 493 patients. From June to July 2019, follow-up results will be released. It plans to submit a permit application to the FDA as soon as the results are released.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: / Editorial Div. 02-578-0434 / 010-2442-9446. Email:
  • Publisher: Monica Younsoo Chung. Chief Editorial Writer: Kim Hyoung-joong. CEO: Lee Kap-soo. Editor: Jung Yeon-jin.
  • Juvenile Protection Manager: Yeon Choul-woong. IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.